Invasive Disease Caused by Group A Streptococcus (GAS) - a Prospective Study (DICAR)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Invasive Group A Beta-Haemolytic Streptococcal Disease
- Sponsor
- Tampere University Hospital
- Enrollment
- 45
- Locations
- 2
- Primary Endpoint
- Severe invasive GAS disease
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The goal of this study is to gain important knowledge on the pathogenesis and prognostic factors in severe invasive group A streptococcal (GAS) infections, as well as the effects of individual characteristics of both the pathogen and the patient on disease severity. The aim is to recruit a minimum of 60 patients from Tampere and Turku University Hospitals in 2-3 years to gather a suitably wide spectrum of manifestations of the disease, and gather genetic, transcriptomic and diagnostic data on both the patients and pathogens in an effort to further our understanding of the pathogenesis of severe invasive GAS disease.
Detailed Description
Invasive group A streptococcal (GAS) infection is a severe, life threatening disease. New prognostic markers are needed to better identify patients at risk of severe complications to better improve their care. By advancing understanding of the mechanisms of severe disease, treatments may be found to hinder the processes behind them. It is likely that different individuals react differently to the same microbe. From previous incidence data the investigators have estimated that it will be possible to recruit a minimum of 60 patients over the course of 2-3 years from Tampere and Turku University Hospitals. This sample size should contain a reasonably wide array of infections with varying stages of severity. The investigators will then gather genetic and transcriptomic data on these patients at three time points, as well as salival samples for antibody analysis, and throat cultures to screen for carriage of the pathogen in question. The genome of all the GAS strains obtained from the patients will also be sequenced. From this the investigators hope to derive information pertaining to the interplay of the patients immunologic response and the pathogens inherent characteristics.
Investigators
Ville Kaila
Clinical investigator
Tampere University Hospital
Eligibility Criteria
Inclusion Criteria
- •Adult patients who have been diagnosed with invasive group A streptococcal disease and are willing to participate
Exclusion Criteria
- •Underage patients are excluded
Outcomes
Primary Outcomes
Severe invasive GAS disease
Time Frame: Four month follow up
GAS infection leading to death, complications or disability